European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Primary Urethral Carcinoma

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
No results found
  1. Introduction
  2. Methods
  3. Epidemiology Aetiology And Pathology
  4. Staging And Classification Systems
  5. Diagnostic Evaluation And Staging
  6. Prognosis
  7. Disease Management
  8. Follow Up
  9. References
  10. Conflict Of Interest
  11. Citation Information
3. Epidemiology Aetiology And Pathology
  • 1. Introduction
  • 2. Methods
  • 3. Epidemiology Aetiology And Pathology
  • 4. Staging And Classification Systems
  • 5. Diagnostic Evaluation And Staging
  • 6. Prognosis
  • 7. Disease Management
  • 8. Follow Up
  • 9. References
  • 10. Conflict Of Interest
  • 11. Citation Information
  • No elements found. Consider changing the search query.
  • List is empty.

3. EPIDEMIOLOGY AETIOLOGY AND PATHOLOGY

3.1. Epidemiology

Primary urethral carcinoma is considered a rare cancer, accounting for < 1% of all genitourinary malignancies [6] (ICD-O3 topography code: C68.0) [7]. In 2013, the prevalence of urethral carcinoma in the 28 European Union countries was 3,986 cases with an estimated annual incidence of 1,504 new cases, with a male/female prevalence of 2.9:1 [8]. Likewise, in an updated analysis of the Surveillance, Epidemiology and End Results (SEER) database (2004–2016), the incidence of primary urethral carcinoma peaked in the > 75 years age group (7.6/million). The age-standardised rate was 4.3/million in men and 1.5/million in women and was almost negligible in those aged < 55 years (0.2/million) [9]. After matching for tumour and patient characteristics, women present with higher disease stage and exhibited higher cancer-specific mortality (CSM) [10].

3.2. Aetiology

For male primary urethral carcinoma, various predisposing factors have been reported, including urethral strictures [11,12], chronic irritation after intermittent catheterisation/urethroplasty [13-15], external beam irradiation therapy (EBRT) [16], radioactive seed implantation [17], chronic urethral inflammation/urethritis following sexually transmitted infections (i.e., condylomata associated with human papilloma virus 16) [18,19] and lichen sclerosis [12]. In female urethral carcinoma, urethral diverticula [20-22] and recurrent urinary tract infections [23] have been associated with primary urethral carcinoma. Mid-urethral sling meshes have not been associated with an increased risk of primary urethral carcinoma [24]. Clear-cell adenocarcinoma (AC) may also have a congenital origin [25,26].

3.3. Histopathology and genomic profiling

Both the Surveillance of Rare Cancers in Europe (RARECARE) project and SEER database have reported that urothelial carcinoma (UC) of the urethra is the predominant histological type of primary urethral cancer (54–65%), followed by squamous cell carcinoma (SCC) (16–22%) and AC (10–16%) [8,27].

A SEER analysis of 2,065 men with primary urethral carcinoma (mean age 73 years) found that UC was most common (78%), and SCC (12%) and AC (5%) were significantly less frequent [28]. In women, AC is the more frequent histology (38–46.7%) followed by SCC (25.4–28%), UC (24.9–28%) and other histological entities (6%) [29,30]. Primary UC with unconventional histological subtypes is very rare and has a poor prognosis [31]. An analysis of the SEER database from 2004 to 2016 identified 165 cases of Primary UC with unconventional histological subtypes, 70.3% of which were in women, and reported that Mullerian-type tumour is the most frequent unconventional histology of urethral cancer, followed by melanocytic-type histology [32].

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer